|
| | Cefroxadine Basic information |
| Product Name: | Cefroxadine | | Synonyms: | cxd;CEFROXADINE;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)amino]-3-methoxy-8-oxo-, [6R-[6α,7β(R*)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methoxy-8-oxo-, (6R,7R)-;Oraspor;(6R,7R)-7-[[(2R)-2-Amino-2-(1-cyclohexa-1,4-dienyl)acetyl]amino]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R,7R)-7-[[(R)-Amino(1,4-cyclohexadien-1-yl)acetyl]amino]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;C12979 | | CAS: | 51762-05-1 | | MF: | C16H19N3O5S | | MW: | 365.4 | | EINECS: | 257-391-8 | | Product Categories: | | | Mol File: | 51762-05-1.mol |  |
| | Cefroxadine Chemical Properties |
| Melting point | 170° (dec) | | alpha | D20 +87° (c = 1.093 in 0.1N HCl) | | Boiling point | 251°C (rough estimate) | | density | 1.3163 (rough estimate) | | refractive index | 1.6390 (estimate) | | pka | pKa 3.30±0.02(H2O t=35.0 I=0.00)(Approximate) |
| Toxicity | LD50 in mice (mg/kg): >6000 orally; 7090 i.p. (Scartazzini, Bickel, 1978) |
| | Cefroxadine Usage And Synthesis |
| Originator | Oraspor,Ciba Geigy,Switz.,1981 | | Uses | Antibacterial. | | Definition | ChEBI: Cefroxadine is a first-generation cephalosporin antibiotic having methoxy and [(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetyl]amino side groups located at positions 3 and 7 respectively. | | Manufacturing Process | A suspension of 30.64 g (0.2 mol) of D-α-amino-α-(1,4-cyclohexadienyl)-
acetic acid in 600 ml of methylene chloride is cooled under a stream of argon
to 6°C, whereupon hydrogen chloride is passed in for about 30 minutes until
the mixture is saturated. Phosphorpentachloride (62.4 g, 0.3 mol) is added in
two portions. The mixture is stirred for 2 hours at 6°C to 8°C. The colorless
precipitate is filtered off under nitrogen and exclusion of moisture, washed
with methylene chloride and dried for 18 hours at 0.05 mm Hg at room
temperature to give D-α-amino-α-(1,4-cyclohexadienyl)-acetylchloride
hydrochloride in form of colorless crystals.
A suspension of 37.3 g (0.1 mol) of 7β-amino-3-methoxy-3-cephem-4-
carboxylic acid hydrochloride dioxanate in 500 ml methylene chloride is stirred
for 15 minutes at room temparature under an argon atmosphere and treated
with 57.2 ml (0.23 mol) of bis-(trimethylsilyl)acetamide. After 45 minutes the
faintly yellow slightly turbid solution is cooled to 0°C and treated within 10
minutes with 31.29 (0.15 mol) of D-α-amino-α-(1,4-cyclohexadienyl)-acetyl
chloride hydrochloride. Thirty minutes thereafter 15 ml (about 0.21 mol) of
propylene oxide is added and the mixture is further stirred for 1 hour at 0°C:
A cooled mixture of 20 ml of absolute methanol in 200 ml of methylene
chloride is added within 30 minutes, after another 30 minutes the precipitate
is filtered off under exclusion of moisture, washed with methylene chloride
and dried under reduced pressure at room temperature. The obtained
hygroscopic crystals of the hydrochloride of 7β-[D-α-(1,4-cyclohexadienyl)-
acetylamino]-3-methoxy-3-cephem-4-carboxylic acid are stirred into 200 ml of
ice water and the milky solution treated with about 66 ml of cold 2 N sodium
hydroxide solution until pH 3.5 is reached. The solution is clarified by filtration
through diatomaceous earth, washed with ice water, cooled to 0°C and treated
with 20 ml of 2 N sodium hydroxide solution until pH 5.7 is reached. A second
filtration through a glass filter frit results in a clear solution which is treated
with acetone (800 ml) at 0°C. The crystals are filtered washed with
acetone:water (2:1), acetone and diethyl ether and dried for 20 hours at
room temperature and 0.05 mm Hg to give the 7β-[D-α-amino-α-(1,4-
cyclohexadienyl)-acetylamino]-3-methoxy-3-cephem-4-carboxylic acid
dihydrate. | | Therapeutic Function | Antibacterial | | Antimicrobial activity | Cefroxadine is closely related to cefradine, the structure differing
only by the presence of a methoxy group replacing methyl at the C-3 position. The antimicrobial spectrum is identical
to that of cefradine and cefalexin. A dose of
1 g as film-coated tablets produced mean peak plasma levels
of 25 mg/L at 1 h. Absorption is depressed and delayed by
administration with food. The plasma elimination half-life is
0.8 h, rising to 40 h in end-stage renal failure and falling to
3.4 h during hemodialysis. Around 85% of an oral dose is
excreted unchanged in the urine. It is available in Japan. |
| | Cefroxadine Preparation Products And Raw materials |
|
